Tools approved to aid AD diagnosis assess the underlying amyloid pathology, such as amyloid positron emission tomography (PET) or the measurement of amyloid and tau proteins in cerebrospinal fluid (CSF).3 This evidence concerns the gene MAPT and Alzheimer disease.